Zeria Pharmaceutical has filed a patent for a composition containing antibodies targeting TNFa for treating inflammatory bowel diseases like Crohn’s disease and ulcerative colitis. The composition, formulated for oral administration, aims to decrease pH in the large intestinal lumen of patients. GlobalData’s report on Zeria Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Zeria Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Zeria Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zeria Pharmaceutical's grant share as of January 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.

Oral composition for treating inflammatory bowel diseases with tnfa antibodies

Source: United States Patent and Trademark Office (USPTO). Credit: Zeria Pharmaceutical Co Ltd

A recently filed patent (Publication Number: US20240000714A1) discloses a composition for oral administration containing antibodies specific to tumor necrosis factor alpha (TNFa) and functional fragments thereof, formulated for treating inflammatory bowel disease in human patients. The treatment aims to decrease the pH in the large intestinal lumen of the patient, facilitating the uptake and penetration of the active agent into the gastrointestinal wall. The composition includes additives such as buffer agents and acidifiers, with the pH in the large intestinal lumen post-treatment ranging from 5.5 to 6.5.

Furthermore, the patent claims specify that the human patients targeted for this treatment may be in remission or have a mild to moderate form of inflammatory bowel disease. The composition may contain specific antibody fragments like Fab, F(ab')2, scFv, and others, and can be in solid dosage forms like pellets, granules, or tablets coated to prevent premature release of the active agent. The pH in the large intestinal lumen before treatment is noted to be higher than 6.5, with the desired pH range post-treatment falling between 5.7 to 6.3 or 5.9 to 6.1. The concentration of the anti-TNFa antibody or its functional fragment in the large intestinal lumen post-treatment is expected to be in the range of 0.2 to 0.8 mg/ml, highlighting the specificity and dosage considerations of the composition.

To know more about GlobalData’s detailed insights on Zeria Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies